Literature DB >> 26319349

Diabetic Retinopathy.

Andrew M Hendrick1, Maria V Gibson2, Ambar Kulshreshtha2.   

Abstract

The prevalence of diabetes is on the rise globally as are the consequences, such as diabetic retinopathy. Diabetic retinopathy is a leading cause of vision loss in working-age adults in developed countries. Visual impairment as a result of diabetic retinopathy has a significant negative impact on the patient's quality of life and their ability to successfully manage their disease. Glycemic control, blood pressure normalization, and lipid management form the basis for long-term diabetes management and protection from worsening eye disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetic retinopathy; Glycemic control; Nonproliferative diabetic retinopathy; Proliferative diabetic retinopathy; Visual impairment

Mesh:

Substances:

Year:  2015        PMID: 26319349     DOI: 10.1016/j.pop.2015.05.005

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  54 in total

1.  Vestaines, novel vasoactive compounds, isolated from Streptomyces sp. SANK 63697.

Authors:  Yuki Hirota-Takahata; Emi Kurosawa; Yoko Ishimoto; Yuko Iwadate; Masaaki Kizuka; Jun Chiba; Toru Hasegawa; Masahiro Tanaka; Hideki Kobayashi
Journal:  J Antibiot (Tokyo)       Date:  2016-08-17       Impact factor: 2.649

Review 2.  Diabetes Complications in Racial and Ethnic Minority Populations in the USA.

Authors:  J Sonya Haw; Megha Shah; Sara Turbow; Michelle Egeolu; Guillermo Umpierrez
Journal:  Curr Diab Rep       Date:  2021-01-09       Impact factor: 4.810

3.  Kaempferol targets estrogen-related receptor α and suppresses the angiogenesis of human retinal endothelial cells under high glucose conditions.

Authors:  Yan Wu; Qinmei Zhang; Rui Zhang
Journal:  Exp Ther Med       Date:  2017-10-03       Impact factor: 2.447

4.  Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina.

Authors:  Qian-Hui Yang; Yan Zhang; Jing Jiang; Mian-Mian Wu; Qian Han; Qi-Yu Bo; Guang-Wei Yu; Yu-Sha Ru; Xun Liu; Min Huang; Ling Wang; Xiao-Min Zhang; Jian-Min Fang; Xiao-Rong Li
Journal:  Int J Ophthalmol       Date:  2018-06-18       Impact factor: 1.779

5.  Earliest Evidence of Preclinical Diabetic Retinopathy Revealed Using Optical Coherence Tomography Angiography Perfused Capillary Density.

Authors:  Richard B Rosen; Jorge S Andrade Romo; Brian D Krawitz; Shelley Mo; Amani A Fawzi; Rachel E Linderman; Joseph Carroll; Alexander Pinhas; Toco Y P Chui
Journal:  Am J Ophthalmol       Date:  2019-01-26       Impact factor: 5.258

6.  Role of aldose reductase in diabetes-induced retinal microglia activation.

Authors:  Kun-Che Chang; Biehuoy Shieh; J Mark Petrash
Journal:  Chem Biol Interact       Date:  2019-01-23       Impact factor: 5.192

7.  Monocyte chemoattractant protein 1 and fractalkine play opposite roles in angiogenesis via recruitment of different macrophage subtypes.

Authors:  Lei Chen; Gao-Qin Liu; Hong-Ya Wu; Ji Jin; Xue Yin; Dan Li; Pei-Rong Lu
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

8.  Protective effects of SIRT1 in patients with proliferative diabetic retinopathy via the inhibition of IL-17 expression.

Authors:  Shulin Liu; Y U Lin; Xin Liu
Journal:  Exp Ther Med       Date:  2015-11-18       Impact factor: 2.447

9.  Prevalence, Awareness and Determinants of Diabetic Retinopathy in a Screening Centre in Nigeria.

Authors:  Nkiru N Kizor-Akaraiwe; Ifeoma R Ezegwui; Ngozi Oguego; Nkechi J Uche; Ifeoma N Asimadu; Jude Shiweobi
Journal:  J Community Health       Date:  2016-08

10.  Multifocal electroretinogram in diabetic macular edema and its correlation with different optical coherence tomography features.

Authors:  Hassan Khojasteh; Hamid Riazi-Esfahani; Elias Khalili Pour; Hooshang Faghihi; Fariba Ghassemi; Fatemeh Bazvand; Raziyeh Mahmoudzadeh; Mirataollah Salabati; Masoud Mirghorbani; Mohammad Riazi Esfahani
Journal:  Int Ophthalmol       Date:  2019-11-11       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.